Qi Yihang, Wang Xiangyu, Kong Xiangyi, Zhai Jie, Fang Yi, Guan Xiaoxiang, Wang Jing
1Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021 China.
2Department of Laboratory Medicine, Mayo Clinic, Rochester, MN 55902 USA.
Cancer Cell Int. 2019 Jan 31;19:23. doi: 10.1186/s12935-018-0709-6. eCollection 2019.
Inflammatory breast cancer (IBC) is an infrequent but aggressive manifestation of breast cancer, which accounts for 2-4% of all breast cancer cases but responsible for 7-10% of breast cancer-related deaths, and with a 20-30% 10-year overall survival compared with 80% for patients with non-IBC with an unordinary phenotype, whose molecular mechanisms are still largely unknown to date. Discovering and identifying novel bio-markers responsible for diagnosis and therapeutic targets is a pressing need. MicroRNAs are a class of small non-coding RNAs that are capable to post-transcriptionally regulate gene expression of genes by targeting mRNAs, exerting vital and tremendous affects in numerous malignancy-related biological processes, including cell apoptosis, metabolism, proliferation and differentiation. In this study, we review present and high-quality evidences regarding the potential applications of inflammatory breast cancer associated microRNAs for diagnosis and prognosis of this lethal disease.
炎性乳腺癌（IBC）是一种罕见但侵袭性强的乳腺癌表现形式，占所有乳腺癌病例的2%-4%，但却导致7%-10%的乳腺癌相关死亡，其10年总生存率为20%-30%，而非IBC且具有异常表型的患者这一比例为80%，其分子机制至今仍 largely未知。发现并鉴定出负责诊断和治疗靶点的新型生物标志物是当务之急。微小RNA是一类小的非编码RNA，能够通过靶向mRNA在转录后调节基因表达，在众多与恶性肿瘤相关的生物学过程中发挥至关重要且巨大的作用，包括细胞凋亡、代谢、增殖和分化。在本研究中，我们综述了关于炎性乳腺癌相关微小RNA在这种致命疾病的诊断和预后方面潜在应用的现有高质量证据。
